Mississippi Breast Center LLC

10/10/2025

If you see Dr. Ley wearing mismatched work shoes in the near future…give all the credit to his newest rescue/adoptee…STELLA! Shes exceeded all expectation. As do ALL the Ley girls.
She’s officially reached the $1500 mark, in shoe destruction.
(Put your shoes away Dr. Ley🫢)
And she’s tripled in size from initial projections. Way to go Stella.
Have a safe and healthy weekend.

10/09/2025

In response to the NBC article: Dr. Ley wants to clarify a few points.
As with any interview, edits happen.
Here are his after notes.

Dr. Ley:

“Let me first apologize in advance about the NBC article.

My comment was not directed at radiation onvologists, rather the institutions. It was an abbreviation of the entire conversation, as most of the time interviews like that are.
It came across as indelicate, and for that I apologize. I know most are not motivated that way and care about the patient. (She took the one thing I said that could be construed as inflammatory and used it. )
I do believe in IORT, FOR APPROPRIATE PATIENTS. Am about to submit my experience with approximately 300 level 2 oncoplastic patients.

I know some radiation oncologists in our area treat some patients for free, we have many dedicated physicians.
I myself, bill just 172 for IORT, but the way medical coding works with multiple procedures I end up get nothing. Anyone serving patients in Mississippi finds themselves providing a good bit of care for free.”

10/07/2025

Dr. Ley makes national news with his work and experience with IORT.
He’a on a mission to make sure its available to all qualifying breast cancer patients.
Just one way he works to make the breast cancer prognosis and process a bit better for his patients.
(Amy Slayton, quoted in the article, is one of Dr. Ley’s patients. )
Please Share .

The technique, known as IORT, has numerous benefits, surgeons say, but it generates less money for hospitals and radiation oncologists.

06/07/2025

Just another example of how MONEY MONEY MONEY gets in the way of proven medical science. And your health care.

Intraopetative Radiation Therapy “IORT” is under attack. Dr. Ley has performed almost 600 cases in past four years with exceptional results.
“This is another example of patient concerns taking a backseat to money. IORT is cost and time effective for patients, but guess what folks…thats taking reimbursements away from radiation centers. They’re losing money to IORT. And they don’t like it.”
Read my colleagues response for more:



L.A. Breast Chronicles

Urgent Bulletin
May 6, 2025

TARGIT IORT Under Threat, Again

When you last heard from me about Intraoperative Radiotherapy (IORT), I had solicited your assistance in getting the American Society of Therapeutic Radiation Oncology to change a proposed policy that could lead to the loss of insurance coverage for Targeted Intraoperative Radiotherapy (TARGIT) for early-stage breast cancer. Thanks to your outreach efforts, we were also to preserve the option of TARGIT IORT for women across the country.

Unfortunately, we are now facing the same challenge from the American Society of Breast Surgeons which at this moment is considering adopting a policy that will likely lead to many women losing access to Targeted Intraoperative Radiotherapy. Once again, I need you help to stop this from happening.

Here's the underlying issue: Intraoperative radiotherapy is a type of partial breast radiation that is given as a single dose in less that 30 minutes at the time of lumpectomy while the patient is asleep in surgery. By focusing the radiation dose to the walls of lumpectomy cavity, IORT reduces radiation exposure and side effects on nearby organs like the heart, lungs, and skin. In a randomized control trial called the TARGIT-A Trial (in while I and many of you were participants), TARGIT IORT was directly compared to the traditional 4-6 week-long course of daily whole breast radiation given after surgery. In the trial, TARGIT IORT was found to be equally effective as whole breast radiation in terms of long term survival without recurrence. TARGIT IORT was also safer in terms of side effects on the skin, heart and lungs.

Although breast surgeons have generally been among the strongest advocates for IORT, the leaders of the American Society of Breast Surgeons are likely being influenced by their radiation oncology colleagues who have a vested financial interest in opposing IORT. The bottom line (literally!) is that radiation oncologists make much less money doing IORT compared to traditional radiation. Although they make a lot of fuss about a 2-4% difference in IORT effectiveness compared to traditional radiation, the real elephant in the room is $$$.

Here's why targeted TARGIT IORT needs to be protected: TARGIT IORT is a single dose radiation treatment administered in < 30 minutes at the time of lumpectomy. For most (>80%) women, TARGIT IORT completely eliminates the need for a 4-6 week-long course of daily whole breast radiation that is traditionally administered after lumpectomy. (Whole breast radiation is still needed for women with more advanced breast cancer.)

Compared to traditional whole breast radiation, other benefits of TARGIT IORT include the following:

1. TARGIT is a convenient one stop treatment. Lumpectomy and radiation are completed in one visit to the hospital.

2. TARGIT has significantly less radiation exposure to the lungs and heart.

3. TARGIT has significantly less side effects on the breast, including less injury to the skin and no radiation-induced breast shrinkage

4. TARGIT is a patient centered treatment that eliminates the need for women to find time away from work, childcare, and/or homecare as required for other forms of breast radiation that must be administered over multiple days or multiple weeks.

5. TARGIT eliminates the financial burden of prolonged radiation treatments for those who do not have a car or money for gas, share ride, a taxi, or a job that gives them the freedom to take time away from work.

6. TARGIT has superior cosmetic results for women with breast implants who are at greater risk of having poor cosmetic results from whole breast radiation.

7. TARGIT reduces the physical burden of radiation for women with physical limitations or mobility challenges.

8. TARGIT makes it easier for women living in remote locations to preserve their breast rather than undergo mastectomy because that cannot commit to a longer course of radiation.

9. TARGIT does not prevent a woman from also safely receiving the traditional 4–6-week course of whole breast radiation after surgery if final surgical pathology results reveal unexpected high-risk findings most suitable for TARGIT alone.

10. TARGIT reduces the burden of radiotherapy by providing an effective, safer, and more convenient radiation treatment option for women who do not require whole breast radiation.

Critics of TARGIT complaint that targeted IORT has a higher recurrence rate compared to traditional whole breast radiation. Although some forms of IORT have been shown to have a 2-4% higher recurrence rate compared to whole breast radiation, that is NOT the case for TARGIT. Yet, the critics find it convenient to lump all forms of IORT together in their strategy to undermine TARGIT.

However, even IF IORT were associated with a higher risk of breast recurrence, the American Society of Breast Surgeons' proposed stance on IORT in general, and TARGIT IORT in particular, completely disregards patient choice in healthcare decision-making regarding radiotherapy, which is completely out of character for an organization that has built a reputation of promoting patient centered care. With patient centered care, individual patients have the right to balance the pros and cons of various treatment options and choose what suits them best--not what best suits the doctors. Patients also have the right to choose a treatment that has a HIGHER local recurrence rate if they perceive alternative treatments to be undesirable. For example, we routinely respect the right of patients to choose lumpectomy instead of mastectomy, the option to decline radiation altogether, and the option to skip chemotherapy and/or anti-estrogen treatment. In the context of patient centered care, patients should also have the right to choose IORT instead of traditional whole breast radiation

How You Can Help?

If you are interested in helping to preserve IORT as an option for women, please share your views directly with the American Society of Breast Surgeons.

Thank you in advance for helping to protect the right for women to choose their own healthcare.

Dennis R. Holmes, MD, FACS
Breast Cancer Surgeon and Researcher.

01/21/2025

TEACHING THE FUTURE!

Dr. Ley recently attended a specialized workshop in Cincinnati offered by The American Society of Breast Surgeons of which he's a longtime member.
He was one of 15 faculty members from across the country invited to teach this intensive two-day course on ultrasound and oncoplastic procedures. Some of the instructors have even created techniques and equipment to better detect and treat breast cancers.
The "student" attendees are Surgical Oncology Fellows who came to Cincinnati from across the country, Mexico City and Great Britain.

Dr. Ley is proud to have participated. He loves sharing his knowledge and working with young physicians who hope to make their own mark in the fight against breast cancer.

01/10/2025

INSURANCE COMPANY DENIALS!
Dr. Ley’s mantra has always been “Patients First!” It’s an important lesson he learned early in his residency from a beloved mentor.
To this day, he fights for the rights of his patients, often going head-to-head with insurance companies and even the government.

If an MRI is denied, Dr. Ley can use Automated Breast Ultrasound. He can detect cancers as small as 2-3mm. More importantly, he can avoid exposing patients to Gadolinium Contrast which is used with MRI.

Gadolinium Contrast is costly AND it is a metal which can potentially lead to neurological problems. A 2016 Mayo Clinic study showed it can accumulate in neural tissue. That can lead to problems associated with memory loss and brain fog.

According to Dr. Ley, there are other potential effects.
“I just had a patient who experienced total alopecia (hair loss) from Gadolinium Contrast. Fortunately, her hair is growing back. There is little conclusive data about the neurologic effects of gadolinium, but it IS a heavy metal, and that raises my concern.”

Women with BRCA1/2 germline mutations are often denied breast MRI -- despite the fact that the exam is recommended for this population.

01/07/2025

Dr. Ley wants everyone to know he is extremely unhappy with this recent action concerning a convicted Mississippi physician who not only defrauded her patients but put their lives in serious peril.
In Dr. Ley’s opinion: “Dr Sachdeeva perpetrated a horrific fraud on trusting patients, including MY patients, and she deserved LIFE in prison without parole.”
Dr. Ley wants to make clear, this is not a political statement but one of medical ethicacy. Patients First!

What do you think?
Please share

For more, check out this news from our friends at Supertalk MS FM…

A former Mississippi oncologist serving two decades behind bars for a chemotherapy fraud scheme has had her sentence commuted by President Joe Biden.

01/06/2025

Help us help others. That's what life is all about.
As co-chair of this year's 2025 MS Kidney Foundation Gala, Dr. Ley is sponsoring a fun filled weekend to sunny Florida to see singing sensation Teddy Swims in concert at the Seminole Hard Rock Casino.
Please click on this link and donate $25 dollars for your chance to win...and help the kidney kids of Mississippi.

By Mississippi Kidney Foundation Inc.